Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hendler

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Medical Care|June 1, 1996
Outpatient geriatric evaluation and management. Results of a randomized trialR W Toseland, J C O'Donnell, J B Engelhardt, et al.
Big Data|March 23, 2017
Liberal Entity Extraction: Rapid Construction of Fine-Grained Entity Typing SystemsLifu Huang, Jonathan May, Xiaoman Pan, et al.
The Primary Care Companion for CNS Disorders|June 29, 2022
Developing, Losing, and Regaining Trust in the Doctor-Patient RelationshipJames K Rustad, Steven C Schlozman, Reuben A Hendler, et al.
Nuclear Medicine and Biology|November 17, 2001
Amplified delivery of indium-111 to EGFR-positive human breast cancer cellsJ Wang, P Chen, Z F Su, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000
A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancerR M Reilly, R Kiarash, J Sandhu, et al.
European Heart Journal|November 10, 2000
Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional CardiologyC Lotan, Y Rozenman, A Hendler, et al.
Journal of Dental Research|October 14, 2010
Involvement of autoimmunity in the pathogenesis of aggressive periodontitisA Hendler, T K Mulli, F J Hughes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2000
111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFRR M Reilly, R Kiarash, R G Cameron, et al.
The American Journal of Cardiology|April 13, 2000
Minimal heparinization in coronary angioplasty--how much heparin is really warranted?E Kaluski, R Krakover, G Cotter, et al.
Nuclear Medicine Communications|December 5, 2002
A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptorK A Vallis, R M Reilly, P Chen, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Medical Care|June 1, 1996
Outpatient geriatric evaluation and management. Results of a randomized trialR W Toseland, J C O'Donnell, J B Engelhardt, et al.
Big Data|March 23, 2017
Liberal Entity Extraction: Rapid Construction of Fine-Grained Entity Typing SystemsLifu Huang, Jonathan May, Xiaoman Pan, et al.
The Primary Care Companion for CNS Disorders|June 29, 2022
Developing, Losing, and Regaining Trust in the Doctor-Patient RelationshipJames K Rustad, Steven C Schlozman, Reuben A Hendler, et al.
Nuclear Medicine and Biology|November 17, 2001
Amplified delivery of indium-111 to EGFR-positive human breast cancer cellsJ Wang, P Chen, Z F Su, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000
A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancerR M Reilly, R Kiarash, J Sandhu, et al.
European Heart Journal|November 10, 2000
Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional CardiologyC Lotan, Y Rozenman, A Hendler, et al.
Journal of Dental Research|October 14, 2010
Involvement of autoimmunity in the pathogenesis of aggressive periodontitisA Hendler, T K Mulli, F J Hughes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2000
111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFRR M Reilly, R Kiarash, R G Cameron, et al.
The American Journal of Cardiology|April 13, 2000
Minimal heparinization in coronary angioplasty--how much heparin is really warranted?E Kaluski, R Krakover, G Cotter, et al.
Nuclear Medicine Communications|December 5, 2002
A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptorK A Vallis, R M Reilly, P Chen, et al.
Pageof 4